Panelists discuss potential changes to clinical pathways for Bruton tyrosine kinase (BTK) inhibitor therapies as a result of the Inflation Reduction Act (IRA), focusing on how shifting costs and ...

After the SGLT2 inhibitors were shown to benefit patients with type 2 diabetes, reducing cardiovascular events, including hospitalization for heart failure, the next natural research question, ...

Transpire Bio has licensed an inhaled PDE4 inhibitor from China’s Intragrand Pharma as a potential treatment for idiopathic pulmonary fibrosis (IPF), investigating a target already being pursued ...

Bayer’s Vividion Therapeutics has secured the global rights from its partner Roche to the only covalent Werner helicase (WRN) inhibitor to have made it into the clinic.. Vividion and Roche have ...

References: Ferrer receives FDA Fast Track designation for FNP-223 in progressive supranuclear palsy (PSP). News release. Ferrer. June 17, 2025.

An SGLT2 inhibitor helped improve metabolic dysfunction-associated steatohepatitis (MASH) in people with or without type 2 diabetes, a randomized trial in China found.

Pirtobrutinib, a noncovalent, Bruton tyrosine kinase inhibitor (BTKi), has shown clinical efficacy and a favorable safety profile. BRUIN CLL-321 was an open-label, randomized phase III study conducted ...

Insilico Medicine and collaborators reported promising safety and efficacy results from a Phase IIa trial of Rentosertib (known as ISM001-055), a TNIK inhibitor developed using Insilico's ...

Merck, known as MSD outside of the United States and Canada, announced today safety and efficacy results from the open-label phase 1 KANDLELIT-001 study, a clinical trial evaluating MK-1084, an ...

Background: Glutamine is required for the growth and survival of multiple tumor types. CB-839 is a highly selective, reversible, allosteric inhibitor of glutaminase, a choke point in the utilization ...